The adverse effects of long-term l-carnitine supplementation on liver and kidney function in rats

被引：20

作者：

Liu, L. ^{[1
]}

Zhang, D-M ^{[1
]}

Wang, M-X ^{[1
]}

Fan, C-Y ^{[1
]}

Zhou, F. ^{[1
]}

Wang, S-J ^{[1
]}

Kong, L-D ^{[1
]}

机构：

[1] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Jiangsu, Peoples R China

来源：

HUMAN & EXPERIMENTAL TOXICOLOGY | 2015年 / 34卷 / 11期

关键词：

l-carnitine; liver and kidney dysfunction; lipid metabolism; ROS; NLRP3; inflammasome; ORGANIC CATION TRANSPORTERS; ADIPOSE-TISSUE; LIPID-ACCUMULATION; DIABETES-MELLITUS; INFLAMMATION; METABOLISM; EXPRESSION; DISEASE; OCTN2; ALLOPURINOL;

D O I：

10.1177/0960327115571767

中图分类号：

R99 [毒物学（毒理学）];

学科分类号：

100405 ;

摘要：

Levo-Carnitine (l-carnitine) is widely used in health and food. This study was to focus on the adverse effects of 8-week oral supplementation of l-carnitine (0.3 and 0.6 g/kg) in female and male Sprague Dawley rats. l-carnitine reduced body and fat weights, as well as serum, liver, and kidney lipid levels in rats. Simultaneously, hepatic fatty acid -oxidation and lipid synthesis were disturbed in l-carnitine-fed rats. Moreover, l-carnitine accelerated reactive oxygen species production in serum and liver, thereby triggering hepatic NOD-like receptor 3 (NLRP3) inflammasome activation to elevate serum interleukin (IL)-1 and IL-18 levels in rats. Alteration of serum alkaline phosphatase levels further confirmed liver dysfunction in l-carnitine-fed rats. Additionally, l-carnitine may potentially disturb kidney function by altering renal protein levels of rat organic ion transporters. These observations may provide the caution information for the safety of long-term l-carnitine supplementation.

引用

页码：1148 / 1161

页数：14

共 35 条

[1] The Adipose Tissue as an Endocrine Organ [J].

Adamczak, Marcin ;

Wiecek, Andrzej .

SEMINARS IN NEPHROLOGY, 2013, 33 (01) :2-13

[2]

Ali Sanaa Ahmed, 2010, Sci Pharm, V78, P881, DOI 10.3797/scipharm.1006-02

[3] Calcium, ATP, and ROS: a mitochondrial love-hate triangle [J].

Brookes, PS ;

Yoon, YS ;

Robotham, JL ;

Anders, MW ;

Sheu, SS .

AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2004, 287 (04) :C817-C833

[4] The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus [J].

Derosa, G ;

Cicero, AFG ;

Gaddi, A ;

Mugellini, A ;

Ciccarelli, L ;

Fogari, R .

CLINICAL THERAPEUTICS, 2003, 25 (05) :1429-1439

[5] Roles of organic anion transporters in the progression of chronic renal failure [J].

Enomoto, Atsushi ;

Niwa, Toshimitsu .

THERAPEUTIC APHERESIS AND DIALYSIS, 2007, 11 :S27-S31

[6] The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis [J].

Franchi, Luigi ;

Eigenbrod, Tatjana ;

Munoz-Planillo, Raul ;

Nunez, Gabriel .

NATURE IMMUNOLOGY, 2009, 10 (03) :241-247

[7] Nod-like proteins in immunity, inflammation and disease [J].

Fritz, Jorg H. ;

Ferrero, Richard L. ;

Philpott, Dana J. ;

Girardin, Stephen E. .

NATURE IMMUNOLOGY, 2006, 7 (12) :1250-1257

[8]

Fruhbeck Gema, 2008, V456, P1, DOI 10.1007/978-1-59745-245-8_1

[9] Effects of oral L-carnitine supplementation on insulin sensitivity indices in response to glucose feeding in lean and overweight/obese males [J].

Galloway, Stuart D. R. ;

Craig, Thomas P. ;

Cleland, Stephen J. .

AMINO ACIDS, 2011, 41 (02) :507-515

[10] Effect of Inflammation on Molecular Targets and Drug Transporters [J].

Hanafy, Sherif ;

El-Kadi, Ayman O. S. ;

Jamali, Fakhreddin .

JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2012, 15 (03) :361-375

← 1 2 3 4 →